A new pill designed by Eli Lilly to help with weight loss and blood sugar control is showing promise in early studies.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Unlike other GLP-1 drugs that are made from large molecules, orforglipron is a small molecule. That means the body may absorb it more easily, The Wall Street Journal reported. Other companies, ...

Lilly, known for injectable drugs like Zepbound for obesity and Mounjaro and Trulicity for diabetes, is among several ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

After reviewing all the data and considering input from regulators, Pfizer decided to discontinue the danuglipron program.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...